Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (131-140 of 223) with videos related to

Pageof 23
Sort By:
Journal of Cellular and Molecular Medicine|May 16, 2019
Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathwayBin Ma, Xiangguo Duan, Qiunan Zhou, et al.
Frontiers in Oncology|April 5, 2021
Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung CancerJuan Zhou, Jing Zhao, Qingzhu Jia, et al.
Translational Lung Cancer Research|April 23, 2021
Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancerChunxia Su, Xinxin Wang, Juan Zhou, et al.
Clinical Lung Cancer|December 28, 2018
Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase InhibitorsTao Jiang, Jing Zhao, Chao Zhao, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|February 20, 2026
Stabilin-1<sup>+</sup> lipid-associated macrophages promote lung adenocarcinoma liver metastasis and osimertinib resistance through impairing macrophage phagocytosis via SIRPα-CD47 axisQi Wang, Jiuli Zhou, Xuefei Li, et al.
Biological Procedures Online|July 24, 2023
Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistanceJuan Zhou, Xiangling Chu, Jing Zhao, et al.
Thoracic Cancer|March 20, 2019
Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failureJuan Zhou, Chao Zhao, Jing Zhao, et al.
Frontiers in Pharmacology|April 12, 2021
Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional SurveyLuping Zhang, Jun Wang, Bicheng Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Meng Qiao, Tao Jiang, Xinyu Liu, et al.
Journal of Thoracic Disease|October 29, 2019
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancerGuanghui Gao, Meng Qiao, Hongcheng Liu, et al.
Pageof 23

Showing results (131-140 of 223) with videos related to

Sort By:
Pageof 23
Journal of Cellular and Molecular Medicine|May 16, 2019
Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathwayBin Ma, Xiangguo Duan, Qiunan Zhou, et al.
Frontiers in Oncology|April 5, 2021
Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung CancerJuan Zhou, Jing Zhao, Qingzhu Jia, et al.
Translational Lung Cancer Research|April 23, 2021
Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancerChunxia Su, Xinxin Wang, Juan Zhou, et al.
Clinical Lung Cancer|December 28, 2018
Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase InhibitorsTao Jiang, Jing Zhao, Chao Zhao, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|February 20, 2026
Stabilin-1<sup>+</sup> lipid-associated macrophages promote lung adenocarcinoma liver metastasis and osimertinib resistance through impairing macrophage phagocytosis via SIRPα-CD47 axisQi Wang, Jiuli Zhou, Xuefei Li, et al.
Biological Procedures Online|July 24, 2023
Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistanceJuan Zhou, Xiangling Chu, Jing Zhao, et al.
Thoracic Cancer|March 20, 2019
Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failureJuan Zhou, Chao Zhao, Jing Zhao, et al.
Frontiers in Pharmacology|April 12, 2021
Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional SurveyLuping Zhang, Jun Wang, Bicheng Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Meng Qiao, Tao Jiang, Xinyu Liu, et al.
Journal of Thoracic Disease|October 29, 2019
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancerGuanghui Gao, Meng Qiao, Hongcheng Liu, et al.
Pageof 23